Relapse · children, aged 2 to 59 months, with WHO‐defined non‐severe pneumonia and wheeze
Antibiotic therapy showed no clear difference in relapse (children who were 'cured' but developed symptoms within… compared with placebo compared to placebo (low certainty).
1 finding from 1 review
Any measure of 'substantial' pain relief · rotator cuff disease
Shock wave therapy showed no clear difference in pain relief > 50%a compared with placebo (low certainty).
1 finding from 1 review
Pain Multiple scalese translated to VAS 0–10 (10 was severe pain)f · rotator cuff disease
Shock wave therapy showed no clear difference in pain Multiple scalese translated to VAS 0–10 (10 was severe pain)f compared with placebo (moderate certainty).
1 finding from 1 review
Functional outcomes · rotator cuff disease
Shock wave therapy probably leads to higher function Multiple scalese translated to Constant 0–100 scale (100… compared with placebo (moderate certainty).
1 finding from 1 review
Participant‐reported success · rotator cuff disease
Shock wave therapy showed no clear difference in participant‐reported success compared with placebo (low certainty).
1 finding from 1 review
Quality of life · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participant withdrawals due to adverse events or treatment intolerance · rotator cuff disease
Shock wave therapy showed no clear difference in number of participant withdrawals due to adverse events or treatment… compared with placebo (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · rotator cuff disease
Shock wave therapy may leads to higher number of participants experiencing any adverse event compared with placebo (low certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
QoL · advanced gastric and oesophago‐gastric junction adenocarcinoma
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy probably leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy may leads to higher tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Daytime sleepiness (ESS): change from baseline. · adults with obstructive sleep apnoea
1 finding from 1 review
Adherence · adults with obstructive sleep apnoea
1 finding from 1 review
Adverse effects Measured as number of participants who discontinued device at end of 2 months · adults with obstructive sleep apnoea
1 finding from 1 review
Quality of life Assessed using SF‐36 or FOSQ · adults with obstructive sleep apnoea
1 finding from 1 review
Sleep quality Assessed by average duration of slow‐wave and REM sleep periods · adults with obstructive sleep apnoea
1 finding from 1 review
Cognitive dysfunction · adults with obstructive sleep apnoea
1 finding from 1 review